Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 49Stomach Neoplasms 10Neoplasms 10HER2-positive Breast Cancer 8Colorectal Neoplasms 8Neoplasm Metastasis 7Esophageal Neoplasms 5Triple Negative Breast Neoplasms 4Salivary Gland Neoplasms 3Ovarian Neoplasms 3Lung Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Adenocarcinoma 3Squamous Cell Carcinoma of Head and Neck 2Pathologic Complete Response 2Pancreatic Neoplasms 2Multiple Myeloma 2Meningeal Neoplasms 2Lymphoma, Non-Hodgkin 2Hematologic Neoplasms 2HER2-positive Early Breast Cancer 2Colonic Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Skin Neoplasms 1Resectable HER2-positive Breast Cancer 1Rectal Neoplasms 1

Interventions

pyrotinib 1pertuzumab 1disitamab vedotin 1Trastuzumab 1RC48 antibody 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Metastatic Breast Cancer × Trastuzumab × Clear all
NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡